Zhongzhi Pharmaceutical Holdings Limited stock analysis
Want to see HK:3737 full AI Analyst Report?
Zhongzhi Pharmaceutical Holdings Limited (3737) Stock Price & Analysis
3737 Stock Chart & Stats
- Day’s Range
- HKD 0.63 - HKD 0.66
- 52-Week Range
- HKD 0.50 - HKD 0.98
- Previous Close
- HKD 0.66
- Volume
- N/A
- Average Volume (3M)
- 375.90K
- Market Cap
- HKD 554.78M
- Enterprise Value
- HKD 588.70M
- Total Cash (Recent Filing)
- HKD 185.38M
- Total Debt (Recent Filing)
- HKD 87.63M
- Price to Earnings (P/E)
- 26.1
- Beta
- 0.06
- Next Earnings
- Mar 25, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- May 23, 2025
- Dividend Yield
- 7.63%
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet
Debt-to-equity around 0.21 and equity of roughly HK$1.0–1.1B indicate a conservative capital structure. This reduces financing strain and preserves flexibility to support operations or strategic investment through a weaker earnings period, improving resilience over the next several quarters.
Healthy Gross Margin
Gross margin remained about 54% in 2025 despite the downturn. That comparatively strong product-level profitability suggests the portfolio retains underlying economic value and gives management a base from which to rebuild operating profit if revenue stabilizes and costs are controlled.
Positive Cash Generation
Operating cash flow remained positive and free cash flow was about HK$69.9M in 2025, showing the business still converts activity into cash. This supports ongoing funding needs and reduces reliance on external financing, even though the cash result weakened year over year.
Bears Say
Revenue Contraction
Revenue declined sharply in 2025 after modest growth in 2024, while reported revenue growth was -15.17%. A sustained top-line contraction would weaken scale benefits, reduce funds available for investment, and make recovery dependent on renewed demand across the company's medicine and healthcare channels.
Severe Margin Compression
Net margin compressed to about 1.0% from 4.3% and operating margin fell to roughly 3.2%, leaving a much thinner earnings cushion. This reduces resilience to cost pressure, limits internal reinvestment capacity, and makes profits more sensitive to even modest operating setbacks.
Declining Free Cash Flow
Although free cash flow remained positive, its approximately 48% year-over-year decline highlights weaker cash conversion or greater cash investment needs. Continued volatility could constrain funding for growth, dividends, or operations and diminish the protection provided by current cash generation.
Zhongzhi Pharmaceutical Holdings Limited News
Zhongzhi Pharmaceutical Announces Board and Committee Structure
The latest update is out from Zhongzhi Pharmaceutical Holdings Limited ( ($HK:3737) ). Zhongzhi Pharmaceutical Holdings Limited’s board comprises four executive directors, one non-executive director, and three independent non-executive directors,
Zhongzhi Pharmaceutical Posts Lower Revenue but Slight Profit Gain in First Half 2026
Zhongzhi Pharmaceutical Holdings Limited ( ($HK:3737) ) just unveiled an announcement. Zhongzhi Pharmaceutical Holdings Limited, a Hong Kong-listed pharmaceutical group incorporated in the Cayman Islands, focuses on manufacturing and selling
Zhongzhi Pharmaceutical Sets 2026 AGM to Seek Mandates on Share Buybacks and Issuance
Zhongzhi Pharmaceutical Holdings Limited ( ($HK:3737) ) has issued an announcement. Zhongzhi Pharmaceutical Holdings Limited has called its annual general meeting for 13 May 2026 in Hong Kong, where shareholders
Zhongzhi Pharmaceutical Profit Slumps 82% as Revenue Falls and Dividend Is Scrapped
The latest announcement is out from Zhongzhi Pharmaceutical Holdings Limited ( ($HK:3737) ). Zhongzhi Pharmaceutical Holdings Limited reported a sharp downturn in its 2025 annual results, with revenue falling 21.6%
Zhongzhi Pharmaceutical Plans Governance Overhaul to Meet New HKEX Rules
Zhongzhi Pharmaceutical Holdings Limited ( ($HK:3737) ) has issued an announcement. Zhongzhi Pharmaceutical Holdings Limited, a Cayman-incorporated pharmaceutical group listed in Hong Kong under stock code 3737, has a board
Zhongzhi Pharmaceutical Sets March 2026 Board Meeting to Approve 2025 Results and Potential Dividend
Zhongzhi Pharmaceutical Holdings Limited ( ($HK:3737) ) just unveiled an announcement. Zhongzhi Pharmaceutical Holdings Limited has scheduled a board meeting in Hong Kong on 26 March 2026 to review and
3737 FAQ
What was Zhongzhi Pharmaceutical Holdings Limited’s price range in the past 12 months?
What is Zhongzhi Pharmaceutical Holdings Limited’s market cap?
When is Zhongzhi Pharmaceutical Holdings Limited’s upcoming earnings report date?
How were Zhongzhi Pharmaceutical Holdings Limited’s earnings last quarter?
Is Zhongzhi Pharmaceutical Holdings Limited overvalued?
Does Zhongzhi Pharmaceutical Holdings Limited pay dividends?
What is Zhongzhi Pharmaceutical Holdings Limited’s EPS estimate?
How many shares outstanding does Zhongzhi Pharmaceutical Holdings Limited have?
What happened to Zhongzhi Pharmaceutical Holdings Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Zhongzhi Pharmaceutical Holdings Limited?
What is the TipRanks Smart Score and how is it calculated?
Zhongzhi Pharmaceutical Holdings Limited Stock Smart Score
Company Description
Zhongzhi Pharmaceutical Holdings Limited
Zhongzhi Pharmaceutical Holdings Limited, an investment holding firm based in the People's Republic of China, focuses on the entire lifecycle of pharmaceutical products, from research and development to manufacturing and distribution. Its operations are structured across three main divisions: pharmaceutical production, management of its physical retail pharmacy chain, and its online pharmacy platform. The company offers Chinese patent medicines and traditional Chinese decoction pieces, marketed under prominent brands such as Zeus, Liumian, and Caojinghua. In addition to its core pharmaceutical activities, Zhongzhi also produces and sells food products and traditional Chinese herbs, manages properties, and offers detection and testing services. By the end of 2021, the company managed a network of 398 self-owned retail pharmacies. Of these, 361 were approved for medical insurance payments and are situated in Zhongshan, Guangdong Province, operating under the Zeus brand. Established in 1993, the company's headquarters are also located in Zhongshan, PRC. Crystal Talent Investment Group Limited holds a controlling stake in Zhongzhi Pharmaceutical Holdings Limited.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Ying Feng Lai
- Employees
- 2,168
- Website
- www.zeus.cn
- Address
- CN
Zhongzhi Pharmaceutical Holdings Limited (3737) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 4 | 9 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 6 | 0 | 6 |









